Literature DB >> 11123107

Approach to pulmonary hypertension.

G L Yung1, L J Rubin.   

Abstract

Until recently, many physicians considered pulmonary hypertension a rare and esoteric condition that is difficult to diagnose and nearly impossible to treat. However, pulmonary hypertension can complicate a variety of relatively common diseases and, with the development of new and effective therapies, there is a need for greater awareness of this condition. Pulmonary hypertension should be considered when patients present with unexplained shortness of breath, chest pain, or syncope. The usual delay of 1 to 2 years between onset of symptoms and diagnosis underscores the importance of considering pulmonary hypertension in the differential diagnosis of patients who present with atypical cardiorespiratory symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11123107     DOI: 10.1007/s11926-000-0030-x

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  25 in total

1.  The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

Authors:  H Frank; J Mlczoch; K Huber; E Schuster; H P Gurtner; M Kneussl
Journal:  Chest       Date:  1997-09       Impact factor: 9.410

Review 2.  Pulmonary hypertension in the obstructive sleep apnoea syndrome: prevalence, causes and therapeutic consequences.

Authors:  R Kessler; A Chaouat; E Weitzenblum; M Oswald; M Ehrhart; M Apprill; J Krieger
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

3.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.

Authors:  S M Palmer; L J Robinson; A Wang; J R Gossage; T Bashore; V F Tapson
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

4.  Membrane diffusion and capillary blood volume in chronic thromboembolic pulmonary hypertension.

Authors:  R J Bernstein; R L Ford; J L Clausen; K M Moser
Journal:  Chest       Date:  1996-12       Impact factor: 9.410

Review 5.  Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension.

Authors:  N F Voelkel; R M Tuder
Journal:  Eur Respir J       Date:  1995-12       Impact factor: 16.671

6.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

7.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment.

Authors:  J Sandoval; J Gaspar; T Pulido; E Bautista; M L Martínez-Guerra; M Zeballos; A Palomar; A Gómez
Journal:  J Am Coll Cardiol       Date:  1998-08       Impact factor: 24.094

Review 8.  Acute and chronic hypoxic pulmonary hypertension.

Authors:  T Higenbottam; G Cremona
Journal:  Eur Respir J       Date:  1993-09       Impact factor: 16.671

9.  Do patients with primary pulmonary hypertension develop extensive central thrombi?

Authors:  K M Moser; P F Fedullo; W E Finkbeiner; J Golden
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

10.  Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension.

Authors:  O Raffy; R Azarian; F Brenot; F Parent; O Sitbon; P Petitpretz; P Hervé; P Duroux; A T Dinh-Xuan; G Simonneau
Journal:  Circulation       Date:  1996-02-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.